Friday, 21 Feb 2020

Biologic/Novel Rx

Datesort descending Type Title Save
25 May 2015 Social SWITCH-RA study: compare RTX vs 2nd TNFi after TNFi fail; RTX better than TNFi, esp in RF+ and inefficacy failures.
25 May 2015 News RA Sarilumab Trials Meet Primary Endpoints
26 May 2015 Social 139TNFi failures switched to RTX, ABA, other TNFi- all equally effective. 80/139 cont Rx@1yr. RTX most cost effective
26 May 2015 News Amgen Halts Development of Brodalumab
26 May 2015 Blog How I Choose Biologics
27 May 2015 News Medicare D and Costly Biologics
31 May 2015 Social Autoinjector market expected to grow to $2.5 billion by 2020.
31 May 2015 News Biologics Spoil Cost Containment Efforts
02 Jun 2015 Social FDA Guidance: #Biosimilars need fingerprint-like analytics w/ reference drug & ACR20 efficacy falling betw goalposts
03 Jun 2015 News 30% of RA Patients Use Biologics as Monotherapy
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx
15 Jun 2015 News Expanding Global Biosimilar Market
17 Jun 2015 Social Metanalysis of 7 RCTs compares high vs low dose RTX in RA shows little clinical difference. Better Xray w/ high dose
19 Jun 2015 News Targeting Autoantibodies in Idiopathic Pulmonary Fibrosis
23 Jun 2015 News Australia Allows Pharmacy Substitution with Biosimilars Without Notice
25 Jun 2015 Social Antecdotal reports of tofacitinib success in resolving depigmentation of vitiligo.
30 Jun 2015 Social PML risk in RA on biologics is <1/1000. 60% of pop is JC virus+; then 23,400 JCV+ pts to recv RTX before 1 PML is Dx.
06 Jul 2015 Social Pfizer has submitted to the FDA (for review) a new once-a-day Xeljanz (tofacitinib) 11 mg qd (equal to 5 mg bid)
09 Jul 2015 Social Promising results with IL-1 inhibitors in Behcent's - remission possible with no serious AEs @DrPetryna
15 Jul 2015 News Xeljanz Warnings on Shingles Updated by FDA